<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>obesity on FinanClub</title>
    <link>https://finan.club/tags/obesity/</link>
    <description>Recent content in obesity on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 15 Jan 2024 09:04:59 +0000</lastBuildDate><atom:link href="https://finan.club/tags/obesity/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>PFE</title>
      <link>https://finan.club/us/pfe/</link>
      <pubDate>Mon, 15 Jan 2024 09:04:59 +0000</pubDate>
      
      <guid>https://finan.club/us/pfe/</guid>
      <description>score:52
Chances: Pfizer appears to be a top value play in the pharmaceutical sector The company&amp;rsquo;s work and investments are likely to pay off eventually Pharmaceutical executives are plotting to break into the lucrative obesity market, presenting potential opportunities for Pfizer Risks: Pfizer shares dropped more than 40% last year, indicating potential risk for investors Legal battles and lawsuits against diversity and inclusion programs could pose reputational and financial risks for the company Score:52 chances characters count - risks characters count = 52</description>
    </item>
    
  </channel>
</rss>
